Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.

2.

For Localized Prostate Cancer, HIFU Is Not Worse Than Prostatectomy.

3.

Oncologist Sued for Double-Billing; Pharmacy Deserts; 'She Loved Scotch and Pizza'

4.

In women with extremely dense breasts, elevated MRI enhancement can help identify cancer risk.

5.

Hospitalization and mortality rates are associated with exposure to the omicron variant of COVID-19 in patients with solid cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot